Pro-Pharmaceuticals and Digna Biotech Sign Agreement to Apply DAVANAT(R) with Novel Drugs to treat Hepatitis C

Pro-Pharmaceuticals and Digna Biotech Sign Agreement to Apply DAVANAT(R) with Novel Drugs to treat Hepatitis C: "NEWTON, Mass.--(BUSINESS WIRE)--Pro-Pharmaceuticals, Inc. (Amex: PRW), a developer of first-in-class carbohydrate therapeutics, today announced it has signed an agreement with Digna Biotech SL of Pamplona, Spain to investigate the application of the Company’s carbohydrate technology platform in combination with Digna’s novel drugs to improve treatment of chronic Hepatitis C infections. "